Activaero GmbH, a technology leader in controlled breathing inhalation devices, today announced that it has closed a further financing round of € 5.0 million ($ 6.8 million). LSP Life Sciences Partners of Amsterdam, the Netherlands, committed € 3.5 million and were joined by the existing investors BioMedPartners AG (advising BioMedInvest LP II), VI Partners AG, Abalis Finance AG, Vesalius Biocapital I SICAR S.A., MedVenture Partners GmbH and existing shareholders who contributed further € 1.5 million. The transaction was advised by MedVenture Partners GmbH.
Activaero will use the proceeds to further develop its proprietary pulmonary drug delivery technology and to establish further clinical activities.
Jörg Neermann, Partner at LSP, will represent LSP in Activaero's supervisory board. He commented: "Our investment is based on the excellent progress made by Activaero and its team since the first financing. The advancements within the current study on severe asthma are highly exciting. We are convinced of the growth potential Activaero is unfolding with its proprietary clinical programs and the impact it's controlled pulmonary delivery technology will have on the treatment of various pulmonary diseases."
Gerhard Scheuch, founder and CEO of Activaero said: "LSP was chosen as a top tier life science investor that will support us and our strategy to provide innovative devices and therapies to patients with severe lung diseases. We are happy to have them on board and we welcome Jörg Neermann to our supervisory board."
AI-powered MRI predicts outcomes in prostate cancer